SterileState raises $10.8M seed to kill ethylene oxide sterilisation
What's the deal? SterileState, a Grand Rapids, Michigan startup, has closed a $10.8 million seed round from 69 investors, according to an SEC filing dated June 22, 2026.
The company is commercialising a nitric oxide-based sterilisation technology that could let medical device makers skip ethylene oxide entirely.
Its product, branded SterileState•78, embeds nitric oxide in a small polymer placed inside sealed device packaging. Once closed, the polymer releases gas that sterilises the contents in roughly four hours.
Traditional ethylene oxide sterilisation ships devices off-site and takes days or weeks, plus extra aeration time to clear toxic residues.
Why now? Ethylene oxide treats roughly half of all sterile US medical devices, but it is a known carcinogen.
In March 2024, the US Environmental Protection AgencyDealroom has a profile for this one. Try Dealroom → finalised its strongest measures yet, slashing emissions from commercial sterilisation facilities. That regulatory squeeze opened a window SterileState aims to fill.
What could go wrong? The FDADealroom has a profile for this one. Try Dealroom → is the biggest hurdle. SterileState has no approval timeline; as of 2023, chief executive officer Kurt Yockey said the team was still working through the regulatory process.
The investor roster is broad and angel-heavy, suggesting the company cast a wide net rather than landing a big institutional check.
By July 2025, SterileState claimed to have tested more than 60 devices from nearly 40 manufacturers, with no material degradation. SCHOTT PharmaDealroom has a profile for this one. Try Dealroom → is reportedly evaluating the technology, but no formal partnerships or contracts have been announced.
The signal: Tightening EPA rules are reshaping a multi-billion-dollar sterilisation bottleneck and opening the door to cleaner alternatives, but SterileState remains an early-stage bet — its patent-pending nitric oxide chemistry, born from a 2013 wound care venture, still has to clear the FDA before any of that opportunity translates into revenue. The angel-heavy roster of 69 investors reflects both the breadth of interest and the absence of a single institutional anchor willing to underwrite that regulatory risk.
Read more: Founderland
Image credit: jurvetson
